Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Cirrhosis | 20 | 2019 | 833 | 3.070 |
Why?
|
| Liver Transplantation | 19 | 2019 | 1037 | 2.640 |
Why?
|
| Glomerular Filtration Rate | 10 | 2023 | 484 | 1.850 |
Why?
|
| Hepatorenal Syndrome | 4 | 2018 | 28 | 1.690 |
Why?
|
| Waiting Lists | 8 | 2020 | 228 | 1.510 |
Why?
|
| Liver Failure, Acute | 4 | 2015 | 88 | 1.480 |
Why?
|
| Kidney Diseases | 4 | 2015 | 477 | 1.350 |
Why?
|
| Kidney | 6 | 2019 | 1346 | 1.320 |
Why?
|
| Fasting | 2 | 2020 | 300 | 1.240 |
Why?
|
| Cystatin C | 4 | 2018 | 51 | 1.230 |
Why?
|
| Creatinine | 9 | 2023 | 382 | 1.130 |
Why?
|
| End Stage Liver Disease | 5 | 2020 | 182 | 1.030 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 126 | 1.020 |
Why?
|
| Renal Insufficiency | 2 | 2018 | 234 | 0.850 |
Why?
|
| Liver | 6 | 2017 | 1757 | 0.840 |
Why?
|
| Metabolic Syndrome | 2 | 2020 | 330 | 0.760 |
Why?
|
| Metabolomics | 3 | 2023 | 417 | 0.730 |
Why?
|
| Factor VIIa | 6 | 2005 | 24 | 0.730 |
Why?
|
| Circadian Clocks | 1 | 2020 | 59 | 0.640 |
Why?
|
| Health Status Disparities | 2 | 2012 | 227 | 0.630 |
Why?
|
| Proteome | 1 | 2020 | 240 | 0.620 |
Why?
|
| Severity of Illness Index | 10 | 2019 | 2894 | 0.590 |
Why?
|
| Ascites | 2 | 2015 | 88 | 0.590 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 467 | 0.580 |
Why?
|
| Middle Aged | 32 | 2020 | 26420 | 0.580 |
Why?
|
| Liver Failure | 4 | 2017 | 89 | 0.540 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 117 | 0.520 |
Why?
|
| Biomarkers | 12 | 2023 | 2976 | 0.520 |
Why?
|
| Liver Cirrhosis, Alcoholic | 3 | 2009 | 36 | 0.510 |
Why?
|
| Patient Discharge | 1 | 2019 | 495 | 0.500 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 23 | 0.490 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 52 | 0.490 |
Why?
|
| Living Donors | 2 | 2014 | 109 | 0.490 |
Why?
|
| Tissue and Organ Procurement | 5 | 2019 | 216 | 0.480 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 628 | 0.470 |
Why?
|
| Renal Plasma Flow | 1 | 2014 | 2 | 0.470 |
Why?
|
| Renal Circulation | 1 | 2014 | 45 | 0.460 |
Why?
|
| Hepatitis C, Chronic | 5 | 2012 | 324 | 0.450 |
Why?
|
| Blood Coagulation Disorders | 3 | 2003 | 101 | 0.440 |
Why?
|
| Vascular Resistance | 1 | 2014 | 186 | 0.430 |
Why?
|
| Humans | 53 | 2023 | 124256 | 0.430 |
Why?
|
| Hemodynamics | 2 | 2014 | 844 | 0.420 |
Why?
|
| Arginine | 1 | 2015 | 330 | 0.420 |
Why?
|
| Adult | 25 | 2019 | 29348 | 0.410 |
Why?
|
| Fatty Liver | 3 | 2014 | 183 | 0.410 |
Why?
|
| Resource Allocation | 1 | 2012 | 52 | 0.380 |
Why?
|
| Male | 29 | 2020 | 60956 | 0.380 |
Why?
|
| Female | 32 | 2020 | 66226 | 0.380 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 717 | 0.360 |
Why?
|
| Aged | 18 | 2019 | 19450 | 0.360 |
Why?
|
| Kidney Transplantation | 3 | 2015 | 634 | 0.360 |
Why?
|
| Valproic Acid | 1 | 2010 | 164 | 0.340 |
Why?
|
| Polyethylene Glycols | 2 | 2008 | 223 | 0.330 |
Why?
|
| Interferon-alpha | 2 | 2008 | 221 | 0.330 |
Why?
|
| Liver Diseases | 2 | 2010 | 366 | 0.310 |
Why?
|
| Graft Rejection | 4 | 2019 | 588 | 0.300 |
Why?
|
| Interferons | 1 | 2008 | 123 | 0.290 |
Why?
|
| Hepatitis B | 2 | 2006 | 160 | 0.290 |
Why?
|
| Liver Neoplasms | 3 | 2009 | 1318 | 0.290 |
Why?
|
| Biological Specimen Banks | 1 | 2008 | 51 | 0.290 |
Why?
|
| Catheter Ablation | 1 | 2009 | 237 | 0.280 |
Why?
|
| HIV | 1 | 2008 | 180 | 0.270 |
Why?
|
| HELLP Syndrome | 1 | 2006 | 18 | 0.260 |
Why?
|
| Risk Factors | 12 | 2019 | 10128 | 0.260 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 232 | 0.260 |
Why?
|
| Bile Ducts | 1 | 2006 | 55 | 0.260 |
Why?
|
| Virus Activation | 1 | 2006 | 87 | 0.260 |
Why?
|
| Vasoconstrictor Agents | 2 | 2018 | 136 | 0.250 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2005 | 6 | 0.250 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 9 | 0.250 |
Why?
|
| Recombinant Proteins | 7 | 2008 | 1392 | 0.250 |
Why?
|
| Hepatitis B virus | 1 | 2006 | 136 | 0.250 |
Why?
|
| Graft Survival | 4 | 2019 | 527 | 0.240 |
Why?
|
| Piperazines | 1 | 2007 | 233 | 0.240 |
Why?
|
| Hypertension, Portal | 1 | 2005 | 78 | 0.230 |
Why?
|
| Tissue Donors | 2 | 2018 | 486 | 0.230 |
Why?
|
| Vena Cava, Inferior | 1 | 2005 | 103 | 0.230 |
Why?
|
| Survival Rate | 4 | 2019 | 2020 | 0.220 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 111 | 0.220 |
Why?
|
| Hepatocytes | 1 | 2005 | 228 | 0.220 |
Why?
|
| United States | 8 | 2017 | 10754 | 0.220 |
Why?
|
| Prochlorperazine | 1 | 2003 | 3 | 0.220 |
Why?
|
| Time Factors | 6 | 2019 | 6263 | 0.220 |
Why?
|
| Pyrimidines | 1 | 2007 | 374 | 0.220 |
Why?
|
| Antiemetics | 1 | 2003 | 23 | 0.220 |
Why?
|
| Jehovah's Witnesses | 1 | 2003 | 15 | 0.220 |
Why?
|
| Splenic Artery | 1 | 2003 | 26 | 0.220 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2003 | 37 | 0.220 |
Why?
|
| Pilot Projects | 2 | 2020 | 1399 | 0.210 |
Why?
|
| Heparin | 1 | 2005 | 228 | 0.210 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 198 | 0.210 |
Why?
|
| Pericardiocentesis | 1 | 2003 | 16 | 0.210 |
Why?
|
| Treatment Outcome | 6 | 2018 | 12277 | 0.210 |
Why?
|
| Postoperative Complications | 3 | 2019 | 3062 | 0.210 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 181 | 0.210 |
Why?
|
| Intracranial Hemorrhages | 1 | 2003 | 73 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 529 | 0.200 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1674 | 0.200 |
Why?
|
| Hepatitis C | 1 | 2006 | 364 | 0.200 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 225 | 0.200 |
Why?
|
| Retrospective Studies | 11 | 2019 | 16223 | 0.200 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 589 | 0.200 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 647 | 0.200 |
Why?
|
| Cholestasis | 1 | 2003 | 154 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2003 | 225 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 938 | 0.180 |
Why?
|
| Sex Factors | 2 | 2018 | 1267 | 0.180 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 505 | 0.180 |
Why?
|
| Necrosis | 2 | 2014 | 206 | 0.170 |
Why?
|
| Databases, Factual | 3 | 2018 | 1174 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1320 | 0.170 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 345 | 0.170 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 133 | 0.160 |
Why?
|
| Comorbidity | 3 | 2013 | 1512 | 0.160 |
Why?
|
| Immune System | 1 | 2020 | 87 | 0.160 |
Why?
|
| Adiposity | 1 | 2020 | 191 | 0.160 |
Why?
|
| Bilirubin | 2 | 2012 | 122 | 0.160 |
Why?
|
| Cytoskeleton | 1 | 2020 | 178 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 236 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 147 | 0.150 |
Why?
|
| Lypressin | 1 | 2018 | 16 | 0.150 |
Why?
|
| Donor Selection | 1 | 2018 | 55 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2018 | 3369 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5107 | 0.140 |
Why?
|
| Narcotics | 1 | 2017 | 63 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2019 | 213 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 358 | 0.140 |
Why?
|
| Drug Therapy | 1 | 2017 | 85 | 0.140 |
Why?
|
| Drug Overdose | 1 | 2017 | 65 | 0.130 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 809 | 0.130 |
Why?
|
| DNA Repair | 1 | 2020 | 588 | 0.130 |
Why?
|
| Proteomics | 1 | 2020 | 487 | 0.130 |
Why?
|
| Models, Biological | 2 | 2013 | 1459 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 286 | 0.120 |
Why?
|
| Adolescent | 7 | 2018 | 19338 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 181 | 0.120 |
Why?
|
| Disease Progression | 3 | 2013 | 2038 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2020 | 813 | 0.120 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 254 | 0.120 |
Why?
|
| Glucose | 1 | 2020 | 885 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2017 | 472 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1017 | 0.120 |
Why?
|
| Cognition | 1 | 2020 | 737 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1415 | 0.120 |
Why?
|
| Prognosis | 4 | 2019 | 4554 | 0.120 |
Why?
|
| Factor VII | 2 | 2005 | 15 | 0.120 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2014 | 3 | 0.120 |
Why?
|
| beta 2-Microglobulin | 1 | 2014 | 32 | 0.120 |
Why?
|
| Lipocalins | 1 | 2014 | 26 | 0.120 |
Why?
|
| Lipocalin-2 | 1 | 2014 | 28 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 46 | 0.110 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 56 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 582 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2015 | 168 | 0.110 |
Why?
|
| Iothalamic Acid | 1 | 2013 | 3 | 0.110 |
Why?
|
| Receptors, Virus | 1 | 2014 | 107 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 1411 | 0.110 |
Why?
|
| Diuretics | 1 | 2014 | 159 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2014 | 4728 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2006 | 2087 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 1306 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 412 | 0.100 |
Why?
|
| Organ Size | 1 | 2012 | 432 | 0.100 |
Why?
|
| Likelihood Functions | 1 | 2011 | 111 | 0.090 |
Why?
|
| Young Adult | 5 | 2019 | 8971 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 550 | 0.090 |
Why?
|
| Sodium | 1 | 2012 | 294 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2010 | 120 | 0.090 |
Why?
|
| Antiviral Agents | 2 | 2006 | 746 | 0.080 |
Why?
|
| Infant | 3 | 2010 | 12473 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2010 | 14065 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 1752 | 0.080 |
Why?
|
| Prevalence | 1 | 2015 | 2425 | 0.080 |
Why?
|
| Ribavirin | 2 | 2006 | 80 | 0.080 |
Why?
|
| Thrombomodulin | 2 | 2005 | 24 | 0.080 |
Why?
|
| Thromboplastin | 2 | 2005 | 17 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2010 | 377 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 6465 | 0.070 |
Why?
|
| Erythrocyte Indices | 1 | 2007 | 14 | 0.070 |
Why?
|
| Prothrombin Time | 1 | 2007 | 36 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 44 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2007 | 69 | 0.070 |
Why?
|
| Biopsy | 2 | 2012 | 1237 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2010 | 1479 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2007 | 79 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 2007 | 98 | 0.070 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2006 | 10 | 0.070 |
Why?
|
| Logistic Models | 1 | 2011 | 1802 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2007 | 98 | 0.070 |
Why?
|
| Benzamides | 1 | 2007 | 106 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2007 | 152 | 0.070 |
Why?
|
| Recurrence | 2 | 2009 | 1425 | 0.070 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2006 | 80 | 0.060 |
Why?
|
| Atrophy | 1 | 2006 | 236 | 0.060 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2005 | 16 | 0.060 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 26 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2006 | 169 | 0.060 |
Why?
|
| Hepatectomy | 1 | 2006 | 110 | 0.060 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 47 | 0.060 |
Why?
|
| Factor VIII | 1 | 2005 | 44 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 1 | 2006 | 153 | 0.060 |
Why?
|
| Phlebography | 1 | 2005 | 51 | 0.060 |
Why?
|
| von Willebrand Diseases | 1 | 2005 | 50 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2004 | 324 | 0.060 |
Why?
|
| Iliac Vein | 1 | 2005 | 34 | 0.060 |
Why?
|
| Dissection | 1 | 2005 | 53 | 0.060 |
Why?
|
| Femoral Vein | 1 | 2005 | 51 | 0.060 |
Why?
|
| Twins, Monozygotic | 1 | 2005 | 117 | 0.060 |
Why?
|
| Child | 3 | 2010 | 24498 | 0.060 |
Why?
|
| Diseases in Twins | 1 | 2005 | 94 | 0.060 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 350 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 1154 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 63 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 87 | 0.060 |
Why?
|
| Fibrinolysis | 1 | 2004 | 38 | 0.060 |
Why?
|
| Collateral Circulation | 1 | 2004 | 45 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 874 | 0.060 |
Why?
|
| Pre-Eclampsia | 1 | 2006 | 221 | 0.060 |
Why?
|
| Jaundice, Obstructive | 1 | 2003 | 5 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 548 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2003 | 42 | 0.050 |
Why?
|
| Triglycerides | 1 | 2006 | 567 | 0.050 |
Why?
|
| Catheterization | 1 | 2005 | 236 | 0.050 |
Why?
|
| Platelet Count | 1 | 2003 | 136 | 0.050 |
Why?
|
| Pregnancy | 2 | 2006 | 7163 | 0.050 |
Why?
|
| Integrins | 1 | 2003 | 82 | 0.050 |
Why?
|
| Epilepsy | 1 | 2010 | 868 | 0.050 |
Why?
|
| Registries | 1 | 2009 | 1410 | 0.050 |
Why?
|
| Mice | 1 | 2020 | 17736 | 0.050 |
Why?
|
| Cause of Death | 2 | 2019 | 468 | 0.050 |
Why?
|
| Colonic Polyps | 1 | 2003 | 81 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 234 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 226 | 0.050 |
Why?
|
| Probability | 2 | 2014 | 323 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2003 | 1182 | 0.040 |
Why?
|
| Incidence | 1 | 2006 | 3085 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 34142 | 0.040 |
Why?
|
| Stents | 1 | 2005 | 884 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 192 | 0.040 |
Why?
|
| Allografts | 1 | 2018 | 190 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 685 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2009 | 1886 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 483 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 128 | 0.030 |
Why?
|
| Camptothecin | 1 | 2014 | 76 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 3575 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2004 | 67 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2121 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 816 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2012 | 101 | 0.020 |
Why?
|
| Serum | 1 | 2012 | 47 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2869 | 0.020 |
Why?
|
| Brain | 1 | 2003 | 3005 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1887 | 0.020 |
Why?
|
| Sepsis | 1 | 2009 | 479 | 0.020 |
Why?
|
| Causality | 1 | 2004 | 83 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 60 | 0.010 |
Why?
|
| P-Selectin | 1 | 2004 | 77 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2004 | 97 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2004 | 100 | 0.010 |
Why?
|
| Hemostasis | 1 | 2004 | 68 | 0.010 |
Why?
|
| Thrombophilia | 1 | 2004 | 42 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 159 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 15 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 209 | 0.010 |
Why?
|
| E-Selectin | 1 | 2003 | 41 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 3415 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 133 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2004 | 241 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 383 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 709 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2003 | 257 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2003 | 239 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2004 | 462 | 0.010 |
Why?
|
| Thrombosis | 1 | 2004 | 519 | 0.010 |
Why?
|
| Myocardium | 1 | 2004 | 997 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 2030 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1526 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 3263 | 0.010 |
Why?
|